Conquering Complexity: The Coming Revolution in Oncology Biomarker Testing
Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.
Ipsos Business Consulting provides practical advice for your business or organisation built on fact-based consulting approaches. We help business leaders and organisations worldwide build, compete, and grow in the marketplace by making idiosyncratic, permanent, and significant improvements in overall performance.